Sputum GeneXpert (MTB/RIF) is a rapid, cartridge-based molecular diagnostic test used to detect Mycobacterium tuberculosis (MTB)—the bacteria that cause tuberculosis (TB)—from a sputum sample (mucus coughed up from the lungs). At the same time, it checks for genetic changes linked to rifampicin resistance, which is an important marker of drug-resistant TB.

This test uses a technique called PCR (polymerase chain reaction) to look for TB DNA. Because it detects genetic material, it can provide results much faster than traditional TB culture—often within a few hours—supporting early detection and timely treatment decisions for respiratory and other infectious diseases.

What the results generally mean:

• “MTB detected”: TB bacteria are present in the sputum. Your clinician will interpret this alongside symptoms, chest imaging, and medical history to confirm active pulmonary TB and start or adjust treatment.

• “MTB not detected”: TB DNA was not found in the sample. This does not always rule out TB—especially if symptoms are strong, the sputum sample is poor quality, or the infection has a low bacterial load. Your doctor may repeat the sputum test, request additional samples, or order other diagnostic tests (e.g., chest X-ray/CT, culture, or additional molecular tests).

• “Rifampicin resistance detected”: The test found genetic markers suggesting resistance to rifampicin, a key first-line TB medicine. This result may indicate drug-resistant TB and usually prompts urgent follow-up, possible confirmatory resistance testing, and a different treatment plan.

• “Rifampicin resistance not detected”: No rifampicin resistance markers were found. Treatment may proceed with standard first-line TB medicines (as clinically appropriate).

• “Invalid/Error/No result”: The test could not be interpreted (for example, due to sample issues or technical factors). A repeat sample is often needed.

Doctors commonly order a Sputum GeneXpert (MTB/RIF) test when someone has symptoms or risk factors for pulmonary tuberculosis or when rapid resistance testing is important. It helps distinguish TB from other causes of persistent cough and supports quick decisions about treatment and infection control.

It may be recommended if you have TB-like symptoms, such as:

• Cough lasting 2–3 weeks or longer

• Coughing up sputum (mucus) and sometimes blood

• Fever, night sweats, chills

• Unexplained weight loss, loss of appetite

• Chest pain, shortness of breath, ongoing fatigue

It’s also commonly done if you have higher risk of TB exposure or severe illness, including:

• Close contact with someone diagnosed with active TB

• Living or working in higher-risk settings (e.g., healthcare facilities, shelters, correctional facilities)

• A weakened immune system (e.g., HIV, certain cancers, transplant medications, long-term steroid use)

• Diabetes, malnutrition, or other conditions that increase susceptibility to infection

• Prior TB treatment, treatment interruption, or suspected relapse (higher risk of drug resistance)

Why clinicians value this test: It can detect TB and possible rifampicin resistance quickly—often faster than smear microscopy and much faster than culture—supporting early diagnosis, appropriate antibiotics, and timely measures to reduce spread to others.

• Pulmonary tuberculosis (TB)
• Rifampicin-resistant tuberculosis (RR-TB)
• Multidrug-resistant tuberculosis (MDR-TB) (often suspected when rifampicin resistance is detected)
• Relapsed or recurrent tuberculosis
• Tuberculosis in people with HIV (TB/HIV co-infection)
• Other causes of chronic cough that may be considered in the differential diagnosis (e.g., bacterial pneumonia, chronic bronchitis) while ruling in/out TB

• Early detection of tuberculosis to start treatment sooner and improve outcomes
• Guiding effective TB treatment by identifying rifampicin resistance (resistance testing)
• Protecting respiratory health by clarifying the cause of a persistent cough
• Reducing transmission of an infectious disease through faster diagnosis and appropriate isolation measures when needed
• Supporting public health screening and outbreak control in high-risk settings
• Monitoring for relapse or treatment failure in people previously treated for TB (as part of a clinician-directed evaluation)